"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 0 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 3 | 5 |
| 2006 | 3 | 1 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 4 | 1 | 5 |
| 2009 | 5 | 3 | 8 |
| 2010 | 4 | 3 | 7 |
| 2011 | 10 | 2 | 12 |
| 2012 | 13 | 0 | 13 |
| 2013 | 7 | 0 | 7 |
| 2014 | 12 | 2 | 14 |
| 2015 | 9 | 0 | 9 |
| 2016 | 11 | 0 | 11 |
| 2017 | 16 | 2 | 18 |
| 2018 | 11 | 1 | 12 |
| 2019 | 15 | 0 | 15 |
| 2020 | 24 | 0 | 24 |
| 2021 | 11 | 2 | 13 |
| 2022 | 18 | 0 | 18 |
| 2023 | 14 | 0 | 14 |
| 2024 | 14 | 0 | 14 |
| 2025 | 13 | 0 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Clinical applications of mass spectrometry in multiple myeloma. Blood Adv. 2025 Dec 23; 9(24):6593-6603.
-
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025 Oct; 646(8086):953-962.
-
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. Drugs. 2025 Oct; 85(10):1231-1251.
-
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events. Am J Hematol. 2025 Oct; 100(10):1839-1850.
-
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. Blood Cancer J. 2025 Jun 18; 15(1):86.
-
Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Sep; 43(25):2766-2771.
-
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma. JAMA Ophthalmol. 2025 06 01; 143(6):507-514.
-
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 05; 23(5):132-140.
-
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025 May; 26(5):596-608.
-
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients. Eur J Haematol. 2025 Jul; 115(1):16-28.